**Financial Highlights:** Q1 FY26 revenue grew 24.5% YoY to 3,570 Cr.

EBITDA reached 850 Cr (+25.8% YoY) with a 23.8% margin.

Profit after tax was 445 Cr.

Net debt stood at 5,249 Cr.

Cash flow from operations converted 99% of EBITDA.

An interim dividend was approved. **Strategic Initiatives & Growth Drivers:** Chronic segments outpaced IPM, driving strong volume growth.

Strategy focuses on expanding super-specialty via BSV integration and in-licensing.

R&D investment targets high-entry barrier products, alongside boosting consumer healthcare penetration. **Business Developments:** BSV consolidation boosted revenue, especially exports.

Key Consumer Healthcare brands saw strong secondary sales.

New product rollouts included Epic ThinX, Nimulid in CHC, and a new US market launch. **Market Position & Competitive Advantage:** Maintained #1 prescription rank for eight years and #2 by volume in the Indian pharma market, growing overall market share to 4.9%. Holds leading positions in key therapy areas and has four #1 ranked consumer healthcare brands. **Investor Implications:** Strong top-line and EBITDA growth highlights solid business and strategic acquisitions.

High cash conversion signals efficiency.

The shift towards high-growth specialty segments indicates positive long-term growth potential.